1. Home
  2. ZSQR vs DRUG Comparison

ZSQR vs DRUG Comparison

Compare ZSQR & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Z Squared Inc. Common Stock

ZSQR

Z Squared Inc. Common Stock

N/A

Current Price

$3.65

Market Cap

697.4M

Sector

Finance

ML Signal

N/A

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$77.42

Market Cap

778.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZSQR
DRUG
Founded
N/A
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
697.4M
778.4M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
ZSQR
DRUG
Price
$3.65
$77.42
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$129.25
AVG Volume (30 Days)
341.1K
176.6K
Earning Date
N/A
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
50.27
N/A
EPS
N/A
N/A
Revenue
$1,363,045.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.71
$38.00
52 Week High
$16.62
$123.75

Technical Indicators

Market Signals
Indicator
ZSQR
DRUG
Relative Strength Index (RSI) 30.57 52.92
Support Level N/A $76.54
Resistance Level $4.20 $83.65
Average True Range (ATR) 0.44 3.86
MACD 0.22 -0.01
Stochastic Oscillator 3.33 37.03

Price Performance

Historical Comparison
ZSQR
DRUG

About ZSQR Z Squared Inc. Common Stock

Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: